Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy-Reference-Cited by-同舟云学术

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Published:2020-03 Issue: Volume:90 Page:106310
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Söderlund Stina,Persson Inger,Ilander Mette,Guilhot Joëlle,Hjorth-Hansen Henrik,Koskenvesa Perttu,Richter Johan,Saussele Susanne,Mustjoki Satu,Olsson-Strömberg Ulla

Funder

Nordic Cancer Union and Lions Uppsala

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference37 articles.

1. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial;Saussele;Lancet Oncol.,2018

2. The biology of chronic myeloid leukemia;Faderl;N. Engl. J. Med.,1999

3. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia;Hochhaus;Leukemia,2009

4. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION);Kantarjian;Blood,2012

5. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia;Saglio;N. Engl. J. Med.,2010

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects;Annals of Hematology;2023-04-29

2. Multiplex proteomics using proximity extension assay for the identification of protein biomarkers predictive of acute graft-vs.-host disease in allogeneic hematopoietic cell transplantation;Clinical Chemistry and Laboratory Medicine (CCLM);2023-01-20

3. Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia;Cancers;2022-09-26

4. Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients;Expert Review of Hematology;2021-12-27

5. Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools;Targeted Oncology;2021-10-18